Cargando…

Key drivers for market penetration of biosimilars in Europe

Background & Objectives: Potential drivers and barriers of biosimilar uptake were mainly analysed through qualitative approaches. The study objective was to conduct a quantitative analysis and identify drivers of biosimilar uptake of all available biosimilars in the European Union (EU). Methods:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rémuzat, Cécile, Dorey, Julie, Cristeau, Olivier, Ionescu, Dan, Radière, Guerric, Toumi, Mondher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328350/ https://www.ncbi.nlm.nih.gov/pubmed/28265349 http://dx.doi.org/10.1080/20016689.2016.1272308

Ejemplares similares

Supply-side and demand-side policies for biosimilars: an overview in 10 European member states
por: Rémuzat, Cécile, et al.
Publicado: (2017)

New drug regulations in France: what are the impacts on market access? Part 2 – impacts on market access and impacts for the pharmaceutical industry
por: Rémuzat, Cécile, et al.
Publicado: (2013)

Market access pathways for cell therapies in France
por: Rémuzat, Cécile, et al.
Publicado: (2015)

New drug regulations in France: what are the impacts on market access? Part 1 – Overview of new drug regulations in France
por: Rémuzat, Cécile, et al.
Publicado: (2013)

Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population
por: Toumi, Mondher, et al.
Publicado: (2020)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
por: Badora, Karolina, et al.
Publicado: (2017)

Value added medicines: what value repurposed medicines might bring to society?
por: Toumi, Mondher, et al.
Publicado: (2016)

Overview of external reference pricing systems in Europe
por: Rémuzat, Cécile, et al.
Publicado: (2015)

Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
por: Jarosławski, Szymon, et al.
Publicado: (2011)

Gene therapies development: slow progress and promising prospect
por: Hanna, Eve, et al.
Publicado: (2017)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
por: Lach, Krzysztof, et al.
Publicado: (2017)

Advanced therapy medicinal products: current and future perspectives
por: Hanna, Eve, et al.
Publicado: (2016)

Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials
por: Hanna, Eve, et al.
Publicado: (2016)

Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions
por: Frybourg, Sandrine, et al.
Publicado: (2015)

A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments
por: Massetti, Marc, et al.
Publicado: (2015)

Attitudes and beliefs of the French public about schizophrenia and major depression: results from a vignette-based population survey
por: Angermeyer, Matthias C, et al.
Publicado: (2013)

The Market Access Society launches a new journal
por: Toumi, Mondher
Publicado: (2013)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
por: Toumi, Mondher, et al.
Publicado: (2017)

Drug repurposing in pharmaceutical industry and its impact on market access: market access implications
por: Murteira, Susana, et al.
Publicado: (2014)

Current process and future path for health economic assessment of pharmaceuticals in France
por: Toumi, Mondher, et al.
Publicado: (2015)

French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends
por: Chouaid, Christos, et al.
Publicado: (2016)

Pharmaceutical expenditure forecast model to support health policy decision making
por: Rémuzat, Cécile, et al.
Publicado: (2014)

EU pharmaceutical expenditure forecast
por: Urbinati, Duccio, et al.
Publicado: (2014)

Novel methodology for pharmaceutical expenditure forecast
por: Vataire, Anne-Lise, et al.
Publicado: (2014)

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
por: Moorkens, Evelien, et al.
Publicado: (2020)

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Introduction of biosimilar insulins in Europe
por: Davies, M., et al.
Publicado: (2017)

Gene therapy randomised clinical trials in Europe – a review paper of methodology and design
por: Ilieva, Krassimira, et al.
Publicado: (2020)

A comparative study of orphan drug prices in Europe
por: Young, Katherine Eve, et al.
Publicado: (2017)

The quality of life of Spanish patients with Huntington's disease measured with H-QoL-I and EQ-5D
por: Dorey, Julie, et al.
Publicado: (2016)

Policies for biosimilar uptake in Europe: An overview
por: Moorkens, Evelien, et al.
Publicado: (2017)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
por: Dutta, Binita, et al.
Publicado: (2019)

The Sertindole Safety Survey: A retrospective analysis under a named patient use programme in Europe
por: Lançon, Christophe, et al.
Publicado: (2008)

An international comparative analysis and roadmap to sustainable biosimilar markets
por: Alnaqbi, Khalid A., et al.
Publicado: (2023)

On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe
por: Jabłońska, Katarzyna, et al.
Publicado: (2021)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Biomedical and Market Issues Surrounding the Advent of Biosimilars
por: Cline, Abigail, et al.
Publicado: (2016)

Cell line access to revolutionize the biosimilars market
por: Gotham, Dzintars
Publicado: (2018)

Systematic literature review on the implicit factors influencing the HTA deliberative process in Europe
por: Monleón, Clara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kh955nvlgetajlf3kr7aqv20rn